Perspectives on the Role of Endocannabinoids in Autism Spectrum Disorders

Mason L. Yeh* and Eric S. Levine*
Department of Neuroscience, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06032, USA

* These authors contributed equally to this work.

Abstract

Autism spectrum disorders (ASDs) are diagnosed on the basis of three behavioral features, namely, (1) deficits in social communication, (2) absence or delay in language and (3) stereotypy. The consensus regarding the neurological pathogenesis of ASDs is aberrant synaptogenesis and synapse function. Further, it is now widely accepted that ASD is neurodevelopmental in nature, placing emphasis on derangements occurring at the level of intra- and intercellular signaling during corticogenesis. At present, there is an ever-growing list of mutations in putative susceptibility genes in affected individuals, preventing effective transformation of knowledge gathered from basic science research to the clinic. In response, the focus of ASD biology has shifted toward the identification of cellular signaling pathways that are common to various ASD-related mutations in hopes that these shared pathways may serve as more promising treatment targets than targeting individual genes or proteins. To this end, the endogenous cannabinoid (endocannabinoid, eCB) system has recently emerged as a promising therapeutic target in the field of ASD research. The eCB system is altered in several neurological disorders, but the role of these bioactive lipids in ASD etiology remains poorly understood. In this perspective, we review current evidence linking eCB signaling to ASDs and put forth the notion that continued focus on eCBs in autism research may provide valuable insight into pathophysiology and treatment strategies. In addition to its role in modulating transmitter release at mature synapses, the eCB signaling system plays important roles in many aspects of cortical development, and disruption of these effects of eCBs may also be related to ASD pathophysiology.

Keywords

Endocannabinoids; Autism; Development; Cortex
Introduction

Autism spectrum disorders (ASDs) comprise a continuum of symptoms and levels of disability that exhibit an early onset and persist through adulthood. ASDs are characterized by deficits in communication and social interaction, as well as by stereotypic behaviors, restricted patterns of interest and sensory issues. Two features distinguish ASDs from other behavioral disorders, clinical and pathogenetic heterogeneity and the distribution of autistic features as a continuum in the general population, dissolving the distinction between “affected” and “unaffected” [1,2]. There are currently no behavioral, genetic, imaging or electrophysiological assays that can specifically diagnose ASDs in the clinic. The prevailing hypothesis in central nervous system (CNS) research is that ASDs may be due to a disruption of the normal process of experience-dependent synaptic development. Several challenges arise, however, in translating our current knowledge base to the clinic. ASD-causing mutations in individual genes that have been uncovered are extremely rare, where each accounts for ~1% of ASD patients. Genome analyses have also revealed the association of copy-number variants and single-nucleotide variants with ASDs. A number of these variants are de novo (not present in either parent). Whole-exome sequencing studies estimate between 400 to 1000 ASD susceptibility genes [3]. In addition to germline mutations, somatic mutations that affect a small subset of neurons can contribute to neurological disorders such as epilepsy, brain malformations and possibly ASDs [4]. In light of these difficulties in determining genetic markers of ASD, current research has moved toward examining cell signaling pathways that may be commonly affected across known ASD-related gene mutations. For example, the metabotropic glutamate receptor (mGluR) and mammalian target of rapamycin (mTOR) pathways have been targeted for developing therapeutic strategies in treating patients with ASDs [5]. Evidence from several mouse models of ASD-related disorders, including Fragile-X Syndrome (FXS) [6–9] and Tuberous Sclerosis (TSC) [10,11] suggest that dysregulation of mTOR and mGluR signaling pathways contribute to deficits in synaptic plasticity and learning and memory. Additionally, there are several converging lines of evidence that indicate mGluR signaling is downstream of mTOR signaling in regulating long-term potentiation (LTP) [12,13] and long-term depression (LTD) [10,11].

Similarly, recent studies provide compelling evidence that disruption of endogenous cannabinoid (endocannabinoid, eCB) signaling may be responsible for synaptic deficits that underlie cognitive and behavioral deficits associated with ASDs. The eCB system has been shown to control emotional responses [14], behavioral reactivity to context [15] and social interaction [16]. Therefore, it is plausible that alterations to eCB signaling may contribute to the autistic phenotype. In this perspective, we review current evidence linking eCB signaling to ASDs and put forth the notion that continued focus on eCBs in autism research may provide valuable insight into pathophysiology and treatment strategies. In addition to its role in modulating transmitter release at mature synapses, the eCB signaling system plays important roles in many aspects of cortical development, and disruption of these effects of eCBs may also be related to ASD pathophysiology. These observations span both rodent and human models in vitro and in vivo. Furthermore, the scope of studies range from eCB-dependent signaling mechanisms, such as synaptic plasticity, to behavioral studies.
examining social reward processing. However, the precise relationship between the eCB system and ASD pathophysiology remains to be clearly delineated.

The Endocannabinoid System

The endogenous cannabinoid (eCB) system is comprised of cannabinoid receptors, endogenous ligands, and their corresponding synthetic and metabolic enzymes. The effects of eCBs are primarily mediated by binding cannabinoid type 1 (CB1) and type 2 (CB2) receptors. Both CB1 and CB2 receptors are G protein-coupled receptors, which couple mainly to G proteins of the G\textsubscript{i} and G\textsubscript{o} classes [17]. Activation of these subclasses of G proteins inhibits adenylyl cyclase and certain voltage-dependent calcium channels and activates inwardly-rectifying potassium channels regulated by mitogen-activated protein kinases. In conjunction, CB1 and CB2 receptor activation exerts diverse consequences across cellular physiology [17].

Neuroanatomical studies have reported abundant CB1 receptor expression in the developing telencephalon as early as embryonic day (E) 11.5 in mouse [18]. The strongest levels of CB1 receptor mRNA at this stage are present in pioneer neurons that occupy the marginal zone of the dorsal cortex, which include Cajal-Retzius cells that are best-known for their role as an instructive signaling cue through secretion of Reelin [19,20]. During mid-stages of cortical development (E13.5–E14.5) in mouse, CB1 receptor expression appears to be upregulated in the intermediate zone (IZ), while continuing to show robust expression in immature neurons accumulating in the overlying cortical plate (CP) [20,21]. Concomitantly, in the ventral forebrain, CB1 receptor expression has been reported in the subpial region of the ganglionic eminence (GE), which gives rise to cortical interneurons, and the primordium of the hippocampus [22]. At later stages of cortical development, CB1 receptor expression is heterogeneously distributed throughout cortical laminae and the hippocampus in both GABAergic and glutamatergic neurons [23–25].

The expression pattern of CB1 receptors has also been examined in human fetal brain using in situ hybridization and binding assays, which provide evidence of strong CB1 receptor expression in the developing cerebral cortex, hippocampus, caudate nucleus, putamen, and cerebellum [26]. Expression of the CB1 receptor has been reported as early as gestational week (GW) 9 in the subventricular zone (SVZ) of the lateral ventricle and Cajal-Retzius cells occupying the MZ, similar to reports in mouse. During the second trimester of gestation, dense labeling of CB1 receptor mRNA is present in fiber-enriched tracts, which, in the adult brain, are practically devoid of CB1 receptor expression [26]. This transient pattern of expression provides further support of the division between eCB signaling during cortical development and identifies the eCB system as a promising target for further examination in the context of neurodevelopmental disorders [27].

The first eCB ligands to be discovered and consequently best characterized are arachidonoyl ethanolamide (anandamide; AEA) and 2-arachidonoyl glycerol (2-AG). A notable feature of both anandamide and 2-AG is that their precursors are present in the lipid membrane. While both anandamide and 2-AG are derivatives of arachidonic acid, their routes of synthesis and degradation in vivo are entirely distinct and mediated by a separate set of enzymes [28].
Anandamide is produced from N-arachidonoyl phosphatidyl ethanol (NAPE) and studies have uncovered two routes of synthesis in the central nervous system: (1) NAPE-PLD [29]; and (2) NAPEphospholipase C (PLC) followed by phosphatase [30]. The synthetic pathway for 2-AG involves sequential hydrolysis of an arachidonoyl-containing phosphatidyl inositol bis-phosphate by PLCβ, followed by subsequent hydrolysis of the resulting diacylglycerol by diacylglycerol lipase (DAGL) [31]. Hydrolysis of an arachidonoyl-containing phosphatidyl inositol bis-phosphate by PLCβ is initiated following stimulation of receptors that activate PLC, such as type I metabotropic glutamate receptors (mGLuRs), M1 or M3 muscarinic receptors, or orexin A, which often leads to production of 2-AG. Two isoforms of DAGL have been identified in nervous tissue, DAGLα and DAGLβ, where DAGLα appears to be the isoform responsible for most 2-AG production that contributes to synaptic plasticity in the mature brain [32–34]. The breakdown of anandamide to AA and ethanolamine is due mainly to the serine hydrolase fatty acid amide hydrolase (FAAH) and FAAH-2 [35,36]. Degradation of 2-AG to AA and glycerol is mediated by monoacylglycerol lipase (MAGL) [37].

**CB1 Receptor Signaling in Cortical Development**

The eCB system is involved in many aspects of early neuronal development and differentiation. Components of the eCB system (including receptors, ligands, synthesizing enzymes and degradative enzymes) are expressed in the developing brain prior to synaptic maturation and neuronal activity (reviewed in [38]). Here, we focus on summarizing CB1 receptor signaling during cortical development and downstream signaling mechanisms that have been shown to play a role in neural progenitor cell maintenance, differentiation and maturation, specifically pertaining to cortical glutamatergic pyramidal neurons. While CB2 receptors may also be involved in cortical development and modulating synaptic activity, their precise role in neuronal signaling remains to be clearly demonstrated [39].

CB1 receptor activity regulates neuronal progenitor cell proliferation and survival. *In vivo* studies have shown that CB1 receptor loss of function causes alterations in cortical and hippocampal development. CB1 receptor knockout mice exhibit reduced levels of cortical progenitor cell proliferation, whereas FAAH-deficient mice show an increase in progenitor cell proliferation [40–42]. Subsequent observations in CB1 receptor knockout mice revealed abnormal cortical development, characterized by defective proliferation of progenitor cell subtypes occupying the ventricular zone (VZ) and SVZ, defective radial migration of immature cortical pyramidal neurons, deficits in axon pathfinding and aberrant subcortical projections [21].

At the level of eCB-mediated cellular signaling pathways, work from Bromberg and colleagues [43] show that CB1 receptor activation can affect over 20 transcription factors that, in turn, mediate neural precursor maintenance, neuronal differentiation and maturation. Specifically, CB1 receptor signaling activates downstream phosphatidylinositol 3-kinase (PI3K) and extracellular signal-related protein kinase (ERK) intracellular pathways to ultimately control transcriptional regulators such as CREB, STAT-3, PAX6 and β-catenin, which are all involved in the control of neural precursor cell proliferation and differentiation. In addition, CB1 receptor coupling with G_{i} mediated inhibition of adenylyl cyclase
decreases cyclic adenosine monophosphate (cAMP), thus disinhibiting the ERK pathway via protein kinase A (PKA) \cite{44,45}. Alternatively, CB1 receptor activation may involve downstream mammalian target of rapamycin complex 1 (mTORC1), a serine/threonine protein kinase that regulates cell growth, proliferation and survival \cite{7}. However, the role of CB1 receptors in mTORC1 signaling during brain development remains to be fully elucidated. In the case of differentiating neurons, CB1 receptor activity has been shown to be coupled to the modulation of the neurogenic transcription factors COUP-TF II (Ctip2) and special AT-rich sequence-binding protein 2 (Satb2). While the mechanism through which this occurs has yet to be elucidated, CB1 receptors are positively coupled to Ctip2 and negatively to Satb2-mediated repression of Ctip2 \cite{46,47}. As a result, CB1 receptor activity can fine-tune the transcriptional program through which neuronal differentiation occurs, where inactivation of CB1 receptors shifts differentiation in favor of upper-layer pyramidal neuron fate versus lower-layer pyramidal neuron fate. This change in neuronal fate-determination, in turn, affects motor function in adulthood \cite{47}.

**eCB Signaling in the Mature CNS**

CB1 receptors are abundantly expressed throughout the central nervous system, notably in the basal ganglia, hippocampus, cerebral cortex, and cerebellum. Cortical and hippocampal CB1 receptor expression predominates in cholecystokinin-positive (CCK\(^+\)) interneurons, but is also present at functional levels in glutamatergic terminals \cite{48–51}. In the dorsal and ventral striatum, CB1 receptor expression is highly enriched in medium spiny neurons, particularly on direct pathway axons as they enter the globus pallidus en route to the substantia nigra \cite{52–55}.

eCBs are potent regulators of synaptic function and profoundly impact a wide range of neural functions, including cognition, motor control, feeding behaviors and pain perception. The primary mechanism through which eCBs regulate synaptic function is via retrograde signaling \cite{56}. This is supported by evidence of presynaptic localization of CB1 receptors and their ability to inhibit neurotransmitter release, coupled with the postsynaptic localization of eCB synthesizing enzymes. Additionally, postsynaptic activity (increases in intracellular calcium and/or activation of \(G_{q/11}\) linked GPCRs) increases eCB production. The first reports of retrograde eCB signaling emerged from groups studying forms of short-term plasticity known as depolarization-induced suppression of inhibition (DSI) \cite{57–59} and depolarization-induced suppression of excitation (DSE) \cite{59–66}. Subsequently, eCBs were also implicated in mediating forms of presynaptic long-term depression (eCB-LTD) at excitatory \cite{67,68} and inhibitory terminals \cite{69–72}. Recently, work from our group has characterized the role of BDNF-trkB receptor signaling in mobilizing eCB synthesis and release. In neocortical layer 2/3, acute application of BDNF rapidly suppresses GABAergic transmission via release of eCBs from the postsynaptic pyramidal cell, which in turn act in a retrograde manner to suppress presynaptic transmitter release \cite{73}. This effect of BDNF is trkB-dependent, requires downstream PLC signaling and is independent of mGluR activation \cite{71}. A follow-up study sought to examine the physiological relevance of BDNF-eCB interactions in the context of activity-dependent long-term depression at inhibitory synapses (iLTD). It was shown that theta burst stimulation (TBS) in layer 2/3 of mouse somatosensory cortical slices induces a form of eCB-mediated iLTD that is independent of

*OBM Neurobiol. Author manuscript; available in PMC 2019 March 08.*
mGluR activation but requires endogenous BDNF-trkB receptor signaling. Furthermore, the expression of this form of eCB-dependent iLTD requires activation of DAGL. Taken together, these results suggest that TBS can induce the release of endogenous BDNF, which triggers DAGL-dependent 2-AG mobilization and CB1 receptor-dependent iLTD [72]. BDNF also induces eCB release at cortical glutamatergic synapses [49]. These studies are a part of a growing body of evidence that BDNF and eCBs interact to regulate synaptic plasticity and further examination may provide clues to underlying pathologies of neurological and psychiatric disorders and suggest strategies for novel therapeutic targets and interventions.

**eCB Signaling in Autism Spectrum Disorders**

A number of lines of evidence suggest that altered eCB signaling may underlie some of the behavioral impairments in ASD. For example, it has been shown that eCBs play a role in controlling emotional responses [14], behavioral reactivity to context [15] and social interaction [16]. Here, we provide an overview of the current evidence of changes to eCB signaling in experimental models of autism, specifically pertaining to the neuregulin 3 (Nlgn3) and Fragile X (FXS) mouse models. Collectively, these studies shed light on the link between alterations in eCB signaling in mediating ASD-related phenotypes and offer an alternative approach to therapeutic intervention and treatment.

Autism is neurodevelopmental in nature and atypical development of circuit connectivity has been suggested to underlie its key phenotypic features. Studies examining idiopathic forms of autism have revealed a set of genes involved in neurodevelopmental processes that mediate the formation, stabilization and pruning of synapses that consistently associate with autism-related phenotypes in animal models [74–76]. Specifically, several members of the neuroligin (NLGN) family of genes, postsynaptic cell adhesion molecules that interact with presynaptic neurexins (NRXNs) to control synapse development and function, have been identified in mouse models of ASDs [77]. Animal models have shown that NLGNs enhance synapse formation in vitro [78], but are not required for synapse formation in vivo [79]. In addition, NLGNs and NRXNs are important organizing molecules for excitatory glutamatergic and inhibitory GABAergic synapses in the mammalian brain [80,81]. Studies that suggest altered neurotransmission resulting from mutations or full gene deletion of NLGNs, particularly NLGN3, have prompted the investigation of the role of eCB signaling in mediating neurotransmitter release in the hippocampus and cortex [82–85].

A recent study by Foldy and colleagues [83] carefully examined one member of the NLGN family, neuroligin-3 (NLGN3) and its association with ASDs. Specifically, two distinct mutations in NLGN3 have been linked with autism-related phenotypes in mouse, (1) a point mutation resulting in an R451C substitution in the neurexin binding domain (Nlgn3R451C) [86] and (2) a deletion of the NLGN3 gene (Nlgn3 KO) [87]. Foldy and colleagues employ previously characterized mouse models of Nlgn3R451C knock-in (KI) and Nlgn3 KO [84,85,88], which have both demonstrated autism-related phenotypes. However, each distinct NLGN3 mouse model exhibits different effects in the context of synaptic and network function, where the Nlgn3R451C KI results in a gain-of-function phenotype that is unrelated to the loss-of-function in the Nlgn3 KO mouse [82,85,89]. In this particular study,
the authors examined GABAergic transmission in the hippocampus of both Nlgn3<sup>R451C</sup> KI and Nlgn3 KO mice between inhibitory basket cells and pyramidal neurons, which are known to play a critical role in cognitive functions specific to the hippocampus [90]. Foldy and colleagues [83] found that CCK-expressing (CCK<sup>+</sup>) inhibitory basket cells in both Nlgn3<sup>R451C</sup> KI and Nlgn3 KO mice exhibited an increase in inhibitory postsynaptic currents (IPSCs), most likely due to an increase in presynaptic release probability. The increase in GABA release probability results from deficits in tonic eCB signaling at presynaptic terminals of CCK<sup>+</sup> interneurons [91]. The authors concluded that in the mouse hippocampus, Nlgn3 is required to establish the release machinery for tonic eCB release to CB1 receptor-containing synapses. Despite these promising results in exploring a particular mutation in the Nlgn3 gene and full gene deletion in mouse hippocampus, there remains the challenge of predicting the relevance of a given mutation for ASD-related phenotypes without directly assessing its effects in a synapse-specific and circuitry-specific manner.

Several studies exploring the Nlgn3<sup>R451C</sup> mutation in the overlying cerebral cortex have revealed differential roles of NLGN3 in regulating synaptic transmission. In an effort to add clarity to the regulatory role of NLGN3, Speed and colleagues [84] expanded on work from the Sudhof group [85] by further investigating the observed increase in inhibitory GABAergic transmission in layers II/III of the somatosensory cortex due to Nlgn3<sup>R451C</sup> KI. In short, Speed and colleagues replicated experiments probing for altered GABAergic transmission in the cortex and narrowed the target mechanisms to altered eCB signaling, not an increase in interneuron number or inhibitory synaptic connections onto pyramidal neurons [84,85]. However, questions remain regarding the respective contribution of tonic eCb signaling and phasic eCB signaling to the altered GABAergic transmission in this model.

In two separate studies, dysfunctional eCB signaling was also identified in the FMR1 KO mouse, a model of FXS [92,93]. However, these studies appear to contradict one another in their conclusions, as Busquets-Garcia and colleagues [92] report gain of function, while Jung and colleagues [93] attribute loss of function of CB1 receptor activity in the absence of FMR1. On the one hand, Busquets-Garcia and colleagues [92] probed for changes in eCB signaling as a result of mGluR5 activation [94] in the CA1 region of the hippocampus in FMR1 mouse model of FXS and reported that CB1 receptor blockade in male FMR1 KO mice normalized cognitive impairment, nociceptive desensitization, susceptibility to audiogenic seizures, overactivation mTOR signaling and altered spine morphology. In addition, blockade of the CB2 receptor normalized anxiolytic-like behavior [92]. On the other hand, Jung and colleagues [93] examined a unique form of mGluR5-dependent long-term depression (LTD) at excitatory synapses of the ventral striatum and prefrontal cortex, which is mediated by the eCB 2-AG. This form of plasticity was absent in FMR1 KO mice, but could be restored with pharmacological enhancement of 2-AG signaling and thus corrected behavioral abnormalities in FMR1 KO mice [93]. Taken together, it is evident that the eCB signalosome is involved in mediating synaptic plasticity in multiple regions of the autistic brain. Further, it appears eCB signaling may exhibit regional specificity. Therefore, while the aforementioned studies in Nlgn3 and FMR1 mouse models of ASD serve to establish the importance of eCB signaling in mediating ASD-related behaviors, much
remains to be elucidated by way of determining both up- and downstream mechanisms that are disrupted in ASDs.

**eCB Signaling in Clinical Studies**

A deficit in theory of mind and empathy has been suggested to underlie atypical social behavior in individuals diagnosed with an ASD. Recent studies have revealed that deficits in reward system circuitry may underpin the lack of social motivation observed in children with ASDs [95–99]. Adaptive reinforcement of social interactions requires long-term synaptic plasticity at excitatory synapses of the nucleus accumbens (NAc) and is dependent on oxytocin (OT). OT, a neuropeptide produced by the paraventricular nucleus of the hypothalamus and released by the posterior pituitary, regulates prosocial behavior and its dysregulation has been implicated in social impairments [100,101]. A recent study by Wei and colleagues [102,103] demonstrated an obligatory role of anandamide in neural circuits of socialization in socially isolated rodents. This study suggested that OT acts as a social reinforcement signal to induce CB1 receptor-dependent long-term depression in medium spiny neurons. Therefore, the enhancement of OT to improve social deficits may be sufficient to trigger anandamide mobilization for proper functioning of the neural circuit. However, this hypothesis may apply to neurological disorders other than ASDs, such as schizophrenia, anxiety or personality disorders [104,105].

Clinical studies examining eye gaze tracking, electroencephalography and functional magnetic resonance imaging suggest clear differences in processing of social rewards in patients with ASDs compared to control subjects [106]. Atypical responses to social rewards from an early age may result in deficits in learning and interpreting the social world, which, in turn, can lead to social behavioral impairments in adulthood. On the other hand, human neuroimaging studies measuring striatal responses to social rewards (happy faces vs. neutral faces) found that common single nucleotide polymorphisms in *CNR1*, the gene coding for the human CB1 receptor, are associated with activity in the central striatal cluster in response to happy, but not disgusted, faces [107]. Given the central role of the ventral striatum in reward processing, this study suggests that changes in *CNR1* are linked to differences in the perception of, and sensitivity to, social rewards. A separate study of the same *CNR1* polymorphism investigated its effect on eye gaze in response to happy faces as opposed to disgusted facial expressions and found that eye gaze duration increased in individuals that carried the *CNR1* polymorphisms. However, there was no difference in eye gaze duration in response to faces expressing disgust [108]. In summary, current evidence strongly implicates alterations to the eCB system in animal models of ASDs and human patients that account for two phenotypic features of ASDs: (1) social reward perception and processing and (2) cortical development. Together, this body of work suggests that distinct elements of the eCB signaling system could be targets for novel therapeutics for treating and managing ASDs. While the ultimate goal is to uncover novel and effective targets, any potential therapeutic approach is unlikely to involve simply activating or inhibiting the eCB system to address specific behaviors or cognitive deficits related to ASDs. Instead, drug targets will require fine-tuning to the precise developmental timeline and to specific pathogenetic mechanisms underlying an individual patient’s disorder.
Looking Forward and Taking the Next Steps

Elucidating the underlying mechanisms of aberrant developmental processes that lead to cognitive and behavioral deficits in ASDs is of paramount importance. It is becoming increasingly apparent from examining mature synapses and circuits that eCB signaling is altered in several neurological diseases. Further, considerable evidence suggests that eCB signaling plays an important role in controlling emotional responses, behavioral reactivity to context and social interaction, all of which are affected in ASDs. Therefore, it is plausible that eCB signaling should be viewed as a potential target for the development of novel therapeutics and treatment strategies in managing symptoms of ASDs in patients. However, there are several issues that must be addressed from the perspective of the etiology of ASDs rooted in abnormal cortical development.

First, we must clarify the aberrant developmental processes that result in deficits in synaptic modulation and circuit connectivity in the mature cortex that in turn underlie cognitive and behavioral symptoms of ASDs. Alternatively, eCB signaling may also play a role in the development of subcortical structures such as the hippocampus, nucleus accumbens and striatum, all of which have featured prominently in behavioral deficits associated with ASDs [83,103,109,110].

Second, the contribution of eCB signaling, be it loss of function or gain of function, during abnormal cortical development remains unresolved. Shedding light on the mechanism(s) through which eCB signaling is altered in development may provide insight as to whether symptoms of ASDs are a result of the developmental role of eCBs or their synaptic modulation, or a combination of the two. It may well be the case that the mechanisms of eCB signaling at the cellular/molecular level during neurodevelopment may differ from their synaptic arrangements in mature systems. ASDs are a uniquely human neuropathological condition. As a result, the few validated rodent models of ASDs remain limited in accurately recapitulating behavioral and cognitive impairments in human patients. To compensate for the short-comings of animal models, studies utilizing induced pluripotent stem cell (iPSC)-derived neurons have provided valuable insight into the pathogenesis of neurological disorders such as ASDs [111]. iPSC technology allows for the generation of patient-specific neurons, which have been used to model FXS [112], Rett Syndrome (RTT) [113], Angelman Syndrome [114], Chromosome 15q11.2–13.1 duplication syndrome (Dup15q) [115] and idiopathic autism [116] because the neuronal subtypes generated model neurons found in the developing brain. However, the eCB system has yet to be examined in the context of these aforementioned neurological disorders using iPSC-derived neurons. Indeed, iPSC-derived neurons may serve as an important model in determining the distinction between developmental eCB signaling mechanisms versus synaptic roles of eCBs.

Finally, these results should be followed up with a thorough examination of the aspects of the ASD phenotype that are a direct result of dysregulated eCB signaling. Advances in our understanding of eCB actions will undoubtedly facilitate pharmacological interventions and further, provide patients the best quality of life possible.
References

1. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord. 2001;31(1):5–17. [PubMed: 11439754]

2. Piven J, Palmer P, Jacobi D, Childress D, Arndt S. Broader autism phenotype: evidence from a family history study of multiple-incidence autism families. Am J Psychiatry. 1997;154(2):185–90. [PubMed: 9016266]

3. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol. 2015;14(11):1109–20. [PubMed: 25891009]

4. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341(6141):1237758. [PubMed: 23828942]

5. Sato A. mTOR, a Potential Target to Treat Autism Spectrum Disorder. CNS Neurol Disord Drug Targets. 2016;15(5):533–43. [PubMed: 27071790]

6. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7. [PubMed: 15219735]

7. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33(2):67–75. [PubMed: 19963289]

8. Kumari D, Bhattacharyya A, Nadel J, Moulton K, Zeak NM, Glicksman A, et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum Mutat. 2014;35(12):1485–94. [PubMed: 25224527]

9. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci. 2010;30(2):694–702. [PubMed: 20071534]

10. Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480(7375):63–8. [PubMed: 22113615]

11. Bateup HS, Johnson CA, Denefrio CL, Saulnier JL, Kornacker K, Sabatini BL. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron. 2013;78(3):510–22. [PubMed: 23664616]

12. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, et al. Reversal of learning deficits in a Tsc2−/− mouse model of tuberous sclerosis. Nat Med. 2008;14(8):843–8. [PubMed: 18568033]

13. Zhou Y, Li W, Shilyansky C, Yao J, Zhang X, Zhou Y, et al. Reversal of learning deficits in a Tsc2−/− mouse model of tuberous sclerosis. Nat Med. 2008;14(8):843–8. [PubMed: 18568033]

14. Marco EM, Scattoni ML, Rapino C, Ceci C, Chaves N, Macri S, et al. Emotional, endocrine and brain anandamide response to social challenge in infant male rats. Psychoneuroendocrinology. 2011;38(6):1024–31. [PubMed: 21198342]

15. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47(Suppl 1):S45–S58. [PubMed: 15461494]

16. Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de Miguel R, et al. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development. 1998;125(16):3179–88. [PubMed: 9671590]

17. Morozov YM, Ben-Ari Y, Freund TF. The spatial and temporal pattern of fatty acid amide hydrolase expression in rat hippocampus during postnatal development. Eur J Neurosci. 2004;20(2):459–66. [PubMed: 15233754]
20. Vitalis T, Laine J, Simon A, Roland A, Lertrier C, Lenkei Z. The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci. 2008;28(9):1705–18. [PubMed: 18973587]

21. Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105(25):8760–5. [PubMed: 18562289]

22. Morozov YM, Torii M, Rakic P, Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb Cortex. 2009;19(Suppl 1):i78–89. [PubMed: 19346272]

23. Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci. 2006;26(21):5628–37. [PubMed: 16723519]

24. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One. 2007;2(8):e709. [PubMed: 17684555]

25. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51(4):455–66. [PubMed: 16908411]

26. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci. 2003;17(9):1747–54. [PubMed: 12752773]

27. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):371–82. [PubMed: 19588184]

28. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. [PubMed: 16968947]

29. Schmid PC, Reddy PV, Natarajan V, Schmid HH. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J Biol Chem. 1983;258(15):9302–6. [PubMed: 6308001]

30. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA. 2006;103(36):13345–50. [PubMed: 16938887]

31. Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol. 2014;171(6):1379–91. [PubMed: 24102242]

32. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163(3):463–8. [PubMed: 14610053]

33. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci. 2010;30(6):2017–24. [PubMed: 20147530]

34. Tanimura A, Yamazaki M, Hashimoto Yamaeta N, Uchigashima M, Kawata S, Abe M, et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron. 2010;65(3):320–7. [PubMed: 20159446]

35. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula, NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384(6604):83–7. [PubMed: 8900284]

36. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281(48):36569–78. [PubMed: 17015445]

37. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 2002;121(1–2):149–58. [PubMed: 12505697]

38. Diaz-Alonso J, Guzman M, Galve-Roperh I. Endocannabinoids via CB(1) receptors act as neurogenic niche cues during cortical development. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3229–41. [PubMed: 23108542]
39. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160(3):467–79. [PubMed: 20590558]
40. Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 2005;19(12):1704–6. [PubMed: 16037095]
41. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci. 2006;26(5):1551–61. [PubMed: 16452678]
42. Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA. 2005;102(52):19115–20. [PubMed: 16357196]
43. Bromberg KD, Ma’ayan A, Neves SR, Iyengar R. Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth. Science. 2008;320(5878):903–9. [PubMed: 18487186]
44. Davis MI, Ronesi J, Lovinger DM. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem. 2003;278(49):48973–80. [PubMed: 14517212]
45. Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C, et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci. 2003;23(6):2371–82. [PubMed: 12657697]
46. Diaz-Alonso J, Aguado T, Wu CS, Palazuelos J, Hofmann C, Garcez P, et al. The CB(1) cannabinoid receptor drives corticospinal motor neuron differentiation through the Ctip2/Satb2 transcriptional regulation axis. J Neurosci. 2012;32(47):16651–65. [PubMed: 23175820]
47. Molyneaux BJ, Arlotta P, Menezes JR, Macklis JD. Neuronal subtype specification in the cerebral cortex. Nat Rev Neurosci. 2007;8(6):427–37. [PubMed: 17514196]
48. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol. 2005;(168):299–325. [PubMed: 16596779]
49. Yeh ML, Selvam R, Levine ES. BDNF-induced endocannabinoid release modulates neocortical glutamatergic neurotransmission. Synapse. 2017;71(5).
50. Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, Hajas N, et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci. 2005;25(29):6845–56. [PubMed: 16033894]
51. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci. 1999;19(11):4544–58. [PubMed: 10341254]
52. Matyas F, Watanabe M, Mackie K, Katona I, Freund TF. Molecular architecture of the cannabinoid signaling system in the core of the nucleus accumbens. Ideggyogy Sz. 2007;60(3–4):187–91. [PubMed: 17451066]
53. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience. 2006;137(1):337–61. [PubMed: 16289348]
54. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393–411. [PubMed: 9460749]
55. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 2007;27(14):3663–76. [PubMed: 17409230]
56. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70–81. [PubMed: 23040807]
57. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 2001;29(3):729–38. [PubMed: 11301031]
58. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001;410(6828):588–92. [PubMed: 11279497]
59. Fortin DA, Trettel J, Levine ES. Brief trains of action potentials enhance pyramidal neuron excitability via endocannabinoid-mediated suppression of inhibition. J Neurophysiol. 2004;92(4):2105–12. [PubMed: 15175370]

60. Fortin DA, Levine ES. Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons. Cereb Cortex. 2007;17(1):163–74. [PubMed: 16467564]

61. Kreitzer AC, Regehr WG. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci. 2001;21(20):RC174. [PubMed: 11588204]

62. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 2001;29(3):717–27. [PubMed: 11301030]

63. Lemtiri-Chlieh F, Levine ES. Lack of depolarization-induced suppression of inhibition (DSI) in layer 2/3 interneurons that receive cannabinoid-sensitive inhibitory inputs. J Neurophysiol. 2007;98(5):2517–24. [PubMed: 17881480]

64. Trettel J, Fortin DA, Levine ES. Endocannabinoid signalling selectively targets perisomatic inhibitory inputs to pyramidal neurons in juvenile mouse neocortex. J Physiol. 2004;556(Pt 1):95–107. [PubMed: 14742727]

65. Trettel J, Levine ES. Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. J Neurophysiol. 2002;88(1):534–9. [PubMed: 12091577]

66. Trettel J, Levine ES. Endocannabinoids mediate rapid retrograde signaling at interneuron right-arrow pyramidal neuron synapses of the neocortex. J Neurophysiol. 2003;89(4):2334–8. [PubMed: 12686587]

67. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci. 2002;5(5):446–51. [PubMed: 11976704]

68. Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA. 2002;99(12):8384–8. [PubMed: 12060781]

69. Chevaleyre V, Castillo PE. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron. 2003;38(3):461–72. [PubMed: 12741992]

70. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–4. [PubMed: 12152079]

71. Zhao L, Levine ES. BDNF-endocannabinoid interactions at neocortical inhibitory synapses require phospholipase C signaling. J Neurophysiol. 2014;111(5):1008–15. [PubMed: 24335212]

72. Zhao L, Yeh ML, Levine ES. Role for Endogenous BDNF in Endocannabinoid-Mediated Long-Term Depression at Neocortical Inhibitory Synapses. eNeuro. 2015;2(2).

73. Zhao L, Levine ES. BDNF evokes release of endogenous cannabinoids at layer 2/3 inhibitory synapses in the neocortex. J Neurophysiol. 2010;104(4):1923–32. [PubMed: 20719932]

74. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci. 2006;29(7):349–58. [PubMed: 16808981]

75. Spooren W, Lindemann L, Ghosh A, Santarelli L. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharmacol Sci. 2012;33(12):669–84. [PubMed: 23084458]

76. Tsai NP, Wilkerson JR, Guo W, Maksimova MA, DeMartino GN, Cowan CW, et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell. 2012;151(7):1581–94. [PubMed: 23260144]

77. Bourgeron T A synaptic trek to autism. Curr Opin Neurobiol. 2009;19(2):231–4. [PubMed: 19545994]

78. Scheiffele P, Fan J, Choih J, Fetter R, Serafini T. Neuroligin expressed in nonneuronal cells triggers presynaptic development in contacting axons. Cell. 2000;101(6):657–69. [PubMed: 10892652]

79. Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, Gottmann K, et al. Neuroligins determine synapse maturation and function. Neuron. 2006;51(6):741–54. [PubMed: 16982420]

80. Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell. 2004;119(7):1013–26. [PubMed: 15620359]
81. Prange O, Wong TP, Gerrow K, Wang YT, El-Husseini A. A balance between excitatory and inhibitory synapses is controlled by PSD-95 and neuroligin. Proc Natl Acad Sci U S A. 2004;101(38):13915–20. [PubMed: 15358863]

82. Etherton M, Foldy C, Sharma M, Tabuchi K, Liu X, Shamloo M, et al. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A. 2011;108(33):13764–9. [PubMed: 2180820]

83. Foldy C, Malenka RC, Sudhof TC. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498–509. [PubMed: 23583622]

84. Speed HE, Masilius I, Gibson JR, Powell CM. Increased Cortical Inhibition in Autism-Linked Neuroligin-3 R451C Mice Is Due in Part to Loss of Endocannabinoid Signaling. PLoS One. 2015;10(10):e0140638. [PubMed: 26469287]

85. Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007;318(5847):71–6. [PubMed: 17823315]

86. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34(1):27–9. [PubMed: 12669065]

87. Sanders SJ, Ercan-Sencicek AG, Hus V, Luo R, Murtha MT, Moreno-De-Luca D, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron. 2011;70(5):863–85. [PubMed: 21658581]

88. Radyushkin K, Hammerschmidt K, Boretius S, Varoquaux F, El-Kordi A, Rommer A, et al. Neurotransmitter-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav. 2009;8(4):141–25. [PubMed: 19234348]

89. Baudouin SJ, Gaudias J, Gerharz S, Hatstatt L, Zhou K, Punnakal P, et al. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science. 2012;338(6103):128–32. [PubMed: 22983708]

90. Lisman J, Buzsaki G. A neural coding scheme formed by the combined function of gamma and theta oscillations. Schizophr Bull. 2008;34(5):974–80. [PubMed: 18599405]

91. Katona I, Freund TF. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci. 2012;35:529–58. [PubMed: 22524785]

92. Busquets-Garcia A, Gomis-Gonzalez M, Guegan T, Agustin-Pavon C, Pastor A, Mato S, et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med. 2013;19(5):603–7. [PubMed: 23542787]

93. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3:1080. [PubMed: 23011134]

94. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci. 2001;21(24):RC188. [PubMed: 11734603]

95. Chevallier C, Kohls G, Troiani V, Brodtkin ES, Schultz RT. The social motivation theory of autism. Trends Cogn Sci. 2012;16(4):231–9. [PubMed: 22425667]

96. Dawson G, Carver L, Meltzoff AN, Panagiotides H, McPartland J, Webb SJ. Neural correlates of face and object recognition in young children with autism spectrum disorder, developmental delay, and typical development. Child Dev. 2002;73(3):700–17. [PubMed: 12038546]

97. Pierce K, Conant D, Hazin R, Stoner R, Desmond J. Preference for geometric patterns early in life as a risk factor for autism. Arch Gen Psychiatry. 2011;68(1):101–9. [PubMed: 20819977]

98. Sims TB, Neufeld J, Johnstone T, Chakrabarti B. Autistic traits modulate frontostriatal connectivity during processing of rewarding faces. Soc Cogn Affect Neurosci. 2014;9(12):2010–6. [PubMed: 24493838]

99. Sims TB, Van Reekum CM, Johnstone T, Chakrabarti B. How reward modulates mimicry: EMG evidence of greater facial mimicry of more rewarding happy faces. Psychophysiology. 2012;49(7):998–1004. [PubMed: 22563935]

100. Parker KJ, Garner JP, Libove RA, Hyde SA, Hornbeak KB, Carson DS, et al. Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and
without autism spectrum disorder. Proc Natl Acad Sci U S A. 2014;111(33):12258–63. [PubMed: 25092315]

101. Baribeau DA, Anagnostou E. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015;9:335. [PubMed: 26441508]

102. Wei D, Lee D, Li D, Daglian J, Jung KM, Piomelli D. A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. Psychopharmacology (Berl). 2016;233(10):1911–9. [PubMed: 26873082]

103. Wei D, Lee D, Cox CD, Karsten CA, Penagarikano O, Geschwind DH, et al. Endocannabinoid signaling mediates oxytocin-driven social reward. Proc Natl Acad Sci U S A. 2015;112(45):14084–9. [PubMed: 26504214]

104. Yuen KW, Garner JP, Carson DS, Keller J, Lembke A, Hyde SA, et al. Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. J Psychiatr Res. 2014;51:30–6. [PubMed: 24405552]

105. Carson DS, Berquist SW, Trujillo TH, Garner JP, Hannah SL, Hyde SA, et al. Cerebrospinal fluid and plasma oxytocin concentrations are positively correlated and negatively predict anxiety in children. Mol Psychiatry. 2015;20(9):1085–90. [PubMed: 25349162]

106. Dawson G, Bernier R, Ring RH. Social attention: a possible early indicator of efficacy in autism clinical trials. J Neurodev Disord. 2012;4(1):11. [PubMed: 22958480]

107. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci. 2006;23(7):1944–8. [PubMed: 16623851]

108. Chakrabarti B, Baron-Cohen S. Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces. Mol Autism. 2011;2(1):10. [PubMed: 21714860]

109. Anderson GR, Aoto J, Tabuchi K, Foldy C, Covy J, Yee AX, et al. beta-Neurexins Control Neural Circuits by Regulating Synaptic Endocannabinoid Signaling. Cell. 2015;162(3):593–606. [PubMed: 26213384]

110. Rothwell PE, Fuccillo MV, Maxeiner S, Hayton SJ, Gokce O, Lim BK, et al. Autism-associated neurexin-3 mutations commonly impair striatal circuits to boost repetitive behaviors. Cell. 2014;158(1):198–212. [PubMed: 24995986]

111. Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414–8. [PubMed: 25132547]

112. Liu J, Koscielska KA, Cao Z, Hulsizer S, Grace N, Mitchell G, et al. Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet. 2012;21(17):3795–805. [PubMed: 22641815]

113. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010;143(4):527–39. [PubMed: 21074045]

114. Fink JJ, Robinson TM, Germain ND, Siros CL, Bolduc KA, Ward AJ, Rigo F, Chamberlain SJ, Levine ES. Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells. Nat Commun. 2017;8:15038. [PubMed: 28436452]

115. Germain ND, Chen PF, Plocik AM, Glatt-Deelely H, Brown J, Fink JJ, et al. Gene expression analysis of human induced pluripotent stem cell-derived neurons carrying copy number variants of chromosome 15q11-q13.1. Mol Autism. 2014;5:44. [PubMed: 25694803]

116. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasinli L, et al. FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell. 2015;162(2):375–90. [PubMed: 26186191]